一线固定疗程纳武利尤单抗联合伊匹木单抗后序贯纳武利尤单抗治疗临床特征多样的不可切除III期或IV期黑色素瘤患者:CheckMate 401
CheckMate 401是一项单臂IIIb期研究,评估纳武利尤单抗联合伊匹木单抗后序贯纳武利尤单抗单药治疗不可切除III-IV期黑色素瘤初治患者的安全性和疗效。533例患者接受治疗,中位随访21.6个月,全治疗人群24个月OS率为63%,脑转移亚组为71%,ECOG PS 2亚组、眼/葡萄膜和黏膜亚组疗效较低。
要点
- 全治疗人群3-5级选择性治疗相关不良事件发生率:胃肠16%、肝脏15%、内分泌11%、皮肤7%。
- 中位随访21.6个月时,全治疗人群24个月OS率为63%,脑转移亚组为71%。
- ECOG PS 2亚组24个月OS率为44%,眼/葡萄膜亚组36%,黏膜亚组38%。
核心结论
- 纳武利尤单抗联合伊匹木单抗后序贯纳武利尤单抗单药治疗在具有不良预后特征的晚期黑色素瘤患者中可耐受。
- 全治疗人群与脑转移患者的疗效相似。
- ECOG PS 2、眼/葡萄膜黑色素瘤和/或黏膜黑色素瘤患者疗效降低,突显这些难治患者持续需要新的治疗选择。
研究设计与样本
- 单臂IIIb期CheckMate 401研究。
- 纳入初治的不可切除III-IV期黑色素瘤患者,共533例接受至少一剂研究药物。
- 治疗方案:纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周一次(共4剂),随后纳武利尤单抗3 mg/kg(方案修订后为240 mg)每2周一次,最长24个月。
- 主要终点为3-5级选择性治疗相关不良事件(TRAEs)的发生率;总生存期(OS)为次要终点。
- 按ECOG PS、脑转移状态和黑色素瘤亚型定义亚组评估结局。
主要发现
- 全治疗人群中,3-5级选择性TRAEs累及胃肠系统16%、肝脏15%、内分泌11%、皮肤7%、肾脏2%、肺1%;各亚组发生率相似。
- 中位随访21.6个月时,全治疗人群24个月OS率为63%。
- ECOG PS 2亚组(仅包括皮肤黑色素瘤患者)24个月OS率为44%。
- 脑转移亚组24个月OS率为71%。
- 眼/葡萄膜黑色素瘤亚组24个月OS率为36%,黏膜黑色素瘤亚组为38%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma. METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg (240 mg following a protocol amendment) once every 2 weeks for ≤24 months. The primary end point was the incidence of grade 3-5 select treatment-related adverse events (TRAEs). Overall survival (OS) was a secondary end point. Outcomes were evaluated in subgroups defined by Eastern Cooperative Oncology Group performance status (ECOG PS), brain metastasis status, and melanoma subtype. RESULTS: In total, 533 patients received at least one dose of study drug. Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups. At 21.6 months' median follow-up, 24-month OS rates were 63% in the all-treated population, 44% in the ECOG PS 2 subgroup (including patients with cutaneous melanoma only), 71% in the brain metastasis subgroup, 36% in the ocular/uveal melanoma subgroup, and 38% in the mucosal melanoma subgroup. CONCLUSION: Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics. Efficacy was similar between the all-treated population and patients with brain metastases. Reduced efficacy was observed in patients with ECOG PS 2, ocular/uveal melanoma, and/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients.
引用
- Dummer R, Corrie P, Gutzmer R, et al. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol. 2023. PMID: 37307514. doi:10.1200/JCO.22.02199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。